Chrysos (ASX:C79) announced a record-breaking financial performance for the first half of FY26, driven by an unprecedented surge in gold sample volumes and the rapid global adoption of its proprietary PhotonAssay technology.
The company reported total revenue of $43.3 million, marking a robust 49% increase over the previous corresponding period.
Even more striking was the growth in EBITDA, which soared by 152% to $14.3 million, effectively pushing EBITDA margins from 20% to a healthy 33%.
The financial momentum is underpinned by a significant expansion of the company’s operational footprint.
During the half, Chrysos deployed four new units and secured eight new lease agreements, with an additional six signed post-period, bringing the total number of contracted units to 72.
High gold prices have fueled exploration activity, while strategic partnerships with industry giants like Newmont, Allied Gold, and major global laboratories have solidified the company's presence in key markets, including South America.
Chrysos has secured a new $200 million debt facility, replacing its existing arrangement with more favorable terms and leaving the company with a bolstered funding position of $72 million.
Chrysos has narrowed its full-year guidance toward the upper end of its targets, forecasting revenue between $80 million–$90 million and EBITDA between $20 million–$27 million for FY26.
At the time of reporting, Chrysos' share price was $7.90.